Form Type: 4

SEC EDGAR Link
Accession Number:0001567619-21-017010
Date:2021-09-09
Issuer: CORVUS PHARMACEUTICALS, INC. (CRVS)
Original Submission Date:

Reporting Person:

GOULD TERRY P
C/O CORVUS PHARMACEUTICALS, INC.
863 MITTEN ROAD, SUITE 102 BURLINGAME, CA 94010

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK, $0.0001 PAR VALUE 2021-09-09 0 $0.00 3,275,616 indirect f2
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 2.6 2021-09-09 deemed execution date A 15,000 (a) 2031-09-09 common stock 15,000 $2.60 15,000 direct
Footnotes
IDfootnote
f1 represents 694,854 shares held by adams street 2011 direct fund lp ("as 2011"), 715,361 shares held by adams street 2012 direct fund lp ("as 2012"), 541,133 shares held by adams street 2013 direct fund lp ("as 2013"), 736,033 shares held by adams street 2014 direct fund lp ("as 2014"), 69,864 shares held by adams street 2015 direct venture/growth fund lp ("as 2015"), 67,769 shares held by adams street 2016 direct venture/growth fund lp ("as 2016"), 87,668 shares held by adams street 2017 direct venture/growth fund lp ("as 2017"), 126,806 shares held by adams street 2018 direct venture/growth fund lp ("as 2018") and 236,128 shares held by adams street venture/growth vi lp ("asvg vi").
f2 adams street partners, llc, as the managing member of the general partner of the general partner of each of as 2011, as 2012, as 2013, as 2014, as 2015, as 2016, as 2017, as 2018 and asvg vi (collectively the "funds"), may be deemed to beneficially own the shares held by the funds. thomas s. bremner, jeffrey t. diehl, elisha p. (terry) gould, robin murray and fred wang, each of whom is a partner of adams street partners, llc (or a subsidiary thereof), may be deemed to have shared voting and investment power over the shares held by the funds. adams street partners, llc and thomas s. bremner, jeffrey t. diehl, elisha p. gould, robin murray and fred wang disclaim beneficial ownership of the shares held by the funds except to the extent of their pecuniary interest therein.
f3 the underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date.
f4 this option was granted to elisha p. gould, a director of corvus pharmaceuticals, inc., who is a partner of adams street partners, llc. adams street partners, llc is the managing member of the general partner of the general partner of each of the funds. by agreement with the funds, mr. gould is deemed to hold the option for the benefit of the funds. the option may be deemed to be indirectly beneficially owned by adams street partners, llc. adams street partners, llc and thomas s. bremner, jeffrey t. diehl, elisha p. gould, robin murray and fred wang, each of whom is a partner of adams street partners, llc (or a subsidiary thereof), disclaim beneficial ownership of the option except to the extent of the pecuniary interest therein.
WhaleWisdom Logo

Elevate your investments